Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies

Journal of Nuclear Medicine

Volumn 37, Issue 12, 1996, Pages 1970-1975

  DeNardo, Diane A ^a   DeNardo, Gerald L ^a   Yuan, Aina ^a   Shen, Sui ^a   DeNardo, Sally J ^a   Macey, Daniel J ^a   Lamborn, Kathleen R ^a   Mahe, Marc ^a   Groch, Mark W ^a   Erwin, William D ^a  

^a NONE

Author keywords

antibody; iodine 131; radiation dosimetry; radioimmunotherapy; therapeutic nuclear medicine; treatment planning

Indexed keywords

ANTIBODY; IODINE 131; TRACER;

ANTIBODY LABELING; ARTICLE; BREAST CANCER; DOSIMETRY; HUMAN; IMAGE ANALYSIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RELIABILITY; STATISTICAL ANALYSIS; TREATMENT PLANNING; TUMOR VOLUME; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; BONE MARROW; BREAST NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 12644301188     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 131I-Lym-1 as a model. Cancer 1994;73:1038-1048.
2. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med 1990;31:1257-1268.
3. DeNardo GL, Raventos A, Hines HH, et al. Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1985;11:335-348.
4. 131I-Lym-1. Int J Biol Markers 1995;10:67-74.
5. Breiman RS, Beck J, Korobkin M, et al. Volume determinations using computed tomography. Am J Raentgenol 1982;138:329-333.
6. Epstein AL, Zimmer AM, Spies SM, et al. Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1). In: Cavalli F, Bonadonna G, Rozencweig GM, eds. Malignant lymphomas and Hodgkin's disease: experimental and therapeutic advances. Boston, MA: Martinus Nijhjoff; 1985:569-577.
7. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-840.
8. DeNardo SJ, Peng J-S, DeNardo GL, Mills SL, Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Nucl Med Biol 1986;13:303-310.
9. Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE. Monoclonal antibodies raised against human lung carcinomas. Cancer Res 1986;46:3917-3923.
10. Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987;84:3439-3443.
11. Beaumier PL, Neuzil D, Yang HM, et al. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med 1986;27:824-828.
12. 131I-Lym-1. Cancer Res 1990;50: 1014s-1016s.
13. DeNardo SJ, O'Grady LF, Hellstrom I, et al. Dose-dependent human biokinetics of L-6 MoAb [Abstract]. J Nucl Med 1989;30(suppl):907.
14. Sokal RR, Rohlf FJ. Biometry. San Francisco, CA: W.H. Freeman: 1969:422.
15. Snyder WS, Ford MR, Warner GC. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. In: MIRD pamphlet 11. New York, NY. Society of Nuclear Medicine: 1978.
16. Macey DJ, DeNardo GL, DeNardo SJ. A treatment planning program for radioimmunotherapy. In: Vaeth, JM, Meyer JL, eds. Frontiers in radiation therapy oncology. San Francisco: S. Karger, Basel: 1990: 123-131.
17. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993;14:587-595.
18. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD pamphlet I. New York, NY: Society of Nuclear Medicine; 1976.
19. Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 1995;20: 117-125.
20. Dillman LT, Von der Lage F. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. In: MIRD pamphlet 10. New York, NY: Society of Nuclear Medicine; 1971.
21. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibod Immunoconj Radiopharm 1990;3:213-233.
22. Freedman GS, Kinsela T, Dwycr A. A correction method for high-count rate quantitative radionuclide angiography. Radiology 1972;104:713-715.
23. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;3:253-255.
24. Hammond ND, Moldofsky PJ, Beardsley MR, Mulhern CB. External imaging techniques for quantitation of distribution of I-131 F(ab′)2 fragments of monoclonal antibody in humans. Med Phys 1984;11:778-783.
25. DeNardo GL, DeNardo SJ, Macey DJ, Mills SL. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled monoclonal antibodies for imaging and therapy. New York, NY: Plenum Publishing Corp; 1988: 293-310.
26. 131I in thyrotoxicosis. Br J Radiol 1979;53:719-726.
27. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.
28. 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibod Immunoconj Radiopharm 1993;6:1-11.
29. Badger CC, Davis J, Nourigat C, et al. Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of I-131. Cancer Res 1991;51:5921-5928.
30. Eary JF, Pollard KR, Durack LD, et al. Post-therapy imaging in high dose I-131 radioimmunotherapy patients. Med Phys 1994;21:1157-1162.
31. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 1993;34:908-917.
32. Wahl RL, Zasadny KR, Kaminski MS. Importance of the terminal portion of tumor time-activity curve in determining tumor dosimetry in radioimmunotherapy. J Nucl Med 1991;32:1314-1315.
33. 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 1988;14:1033-1042.
34. Shen S, DeNardo GL, O'Donnell RT, et al. Practical simplifications for dosimetric models for radioimmunotherapy. Sixth International Rodiopharmaceutical Dosimetry Symposium 1996: in press.